Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-29T04:51:25.166Z Has data issue: false hasContentIssue false
  • English
  • Français

Usage of clozapine and new neuroleptics

Published online by Cambridge University Press:  02 January 2018

Camilla Haw  and
Jean Stubbs
Jean Stubbs
Affiliation:
Head of Pharmacy, St Andrew's Hospital, Billing Road, Northampton NN1 5DG
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Sir: Bristow (Psychiatric Bulletin, August 1999, 23, 478–480) found 9.5% of psychiatrists said their trust restricted clozapine funding. By contrast, the Maudsley National Schizophrenia Fellowship (1998) survey of health authority pharmaceutical advisors reported in the Pharmaceutical Journal found clozapine funding restricted by 45% of health authorities. We have recently carried out a postal questionnaire of members of the UK Psychiatric Pharmacists Group on the use and evaluation of atypical antipsychotics. We received 82 replies giving a response rate of 45%. Eleven per cent of pharmacists reported their trust capped the number of patients prescribed clozapine. However, there was widespread use of measures by trusts to try and limit expenditure on atypicals, restricting the prescribing of atypicals to consultants only and the use of guidelines in which atypicals are not first line treatment for schizophrenia. Only 12% of trusts, our hospital among them, used no cost-containment measures.

Type
Correspondence
Information
Psychiatric Bulletin , Volume 23 , Issue 12: The Journal of Trends in Psychiatric Practice , December 1999 , pp. 749
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1999 Royal College of Psychiatrists

References

Maudsley National Schizophrenia Fellowship (1998) Are patients with schizophrenia denied the best treatment? Pharmaceutical Journal, 261, 847.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.